Safety and Efficacy of ARQ-154 Foam in Adolescent and Adult Subjects With Scalp and Body Psoriasis

Plaque Psoriasis Clinical Trial

Official title:

A Phase 2b, 8-Week, Parallel Group, Double Blind, Vehicle-Controlled Study of the Safety and Efficacy of ARQ-154 Foam 0.3% Administered QD in Adolescents and Adults With Scalp and Body Psoriasis

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04128007
• Other study ID #: ARQ-154-204
• Status: Completed
• Phase: Phase 2
• Start date: January 13, 2020
• Est. completion date: September 25, 2020

Study information

• Verified date: October 2022
• Source: Arcutis Biotherapeutics, Inc.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study will assess the safety and efficacy of ARQ-154 foam vs placebo applied once a day for 56 days by subjects with scalp and body psoriasis

Description:

This is a parallel group, double blind, vehicle-controlled study in which ARQ-154 foam or vehicle is applied once daily x 8 weeks to adolescent and adult subjects with scalp and body psoriasis

Recruitment information / eligibility

• Status: Completed
• Enrollment: 304
• Est. completion date: September 25, 2020
• Est. primary completion date: September 23, 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: 12 Years and older

Eligibility

Inclusion Criteria:

• Participants legally competent to read, write, sign and give informed consent, or, in the case of adolscents, assent with consent of a parent(s) or legal guardian, as required by local laws.

• Males and females ages 12 years and older (inclusive) at the time of consent for assent (for adolescents).

• Scalp psoriasis with an Investigator Global Assessment of Scalp disease severity (S-IGA) of at least Mild ('2') at Baseline.

• A Psoriasis Scalp Severity Index (PSSI) score of at least 6 at Baseline.

• A PASI score of at least 2 (excluding the palms and soles) at Baseline.

• Clinical diagnosis of psoriasis vulgaris of at least 6 months duration as determined by the Investigator. Stable disease for the past 4 weeks.

• Females of childbearing potential (FOCBP) must have a negative serum pregnancy test at Screening (Visit 1) and a negative urine pregnancy test at Baseline (Visit 2).

• Females of non-childbearing potential must either be post-menopausal with spontaneous amenorrhea for at least 12 months or have undergone surgical sterilization.

• Subjects in good health as judged by the Investigator, based on medical history, physical examination, vital signs, serum chemistry labs, hematology values, and urinalysis.

• Subjects are considered reliable and capable of adhering to the Protocol and visit schedule according to the Investigator judgment.

Exclusion Criteria:

• Subjects who cannot discontinue medications and treatments prior to the Baseline visit and during the study according to Excluded Medications and Treatments.

• Planned excessive exposure of treated area(s) to either natural or artificial sunlight, tanning bed or other LED.

• Subjects currently taking lithium or antimalarial drugs.

• Planned initiation or changes to concomitant medication that could, in the opinion of the Investigator, affect psoriasis vulgaris (e.g. beta blockers, ACE inhibitors).

• Current diagnosis of non-plaque forms of psoriasis (e.g., guttate, erythrodermic/exfoliative, palmoplantar only involvement, or pustular psoriasis). Current diagnosis of drug-induced psoriasis.

• Subjects with any condition on the treatment area which, in the opinion of the Investigator, could confound efficacy measurements.

• Known allergies to excipients in ARQ-154.

• Subjects who cannot discontinue the use of strong P-450 cytochrome inhibitors e.g., indinavir, nelfinavir, ritonavir, clarithromycin, itraconazole, ketoconazole, nefazodone, saquinavir, suboxone and telithromycin for two weeks prior to the Baseline visit (Visit 2) and during the study.

• Subjects who cannot discontinue the use of strong P-450 cytochrome inducers e.g., efavirenz, nevirapine, glucocorticoids, barbiturates (including phenobarbital), phenytoin, rifampin, and carbamazepine for two weeks prior to the Baseline visit (Visit 2) and during the study.

• Subjects with PHQ-8 >/= 10 or modified PHQ-A >/= 10 at Screening or Baseline.

• Females who are pregnant, wishing to become pregnant during the study, or are breast-feeding.

• Subjects with any serious medical condition or laboratory abnormality that would prevent study participation or place the subject at significant risk, as determined by the Investigator.

• Subjects with a history of chronic alcohol or drug abuse within 6 months of initiation of the investigational product.

• Subjects with a history of a major surgery within 4 weeks prior to Baseline (Visit 2) or has a major surgery planned during the study.

• Subjects who are unable to communicate, read or understand the local language, or who display another condition, which in the Investigator's opinion, makes them unsuitable for clinical study participation.

• Current or a history of cancer within 5 years with the exception of fully treated skin basal cell carcinoma, cutaneous squamous cell carcinoma or carcinoma in situ of the cervix.

• Subjects with active infection that required oral or intravenous administration of antibiotics, antifungal, or antiviral agents within 7 days of Baseline/Day 0.

• Subjects who are family members of the clinical study site, clinical study staff, or sponsor, or family members residing in the same household of enrolled subjects.

Related Conditions & MeSH terms

• Plaque Psoriasis
• Psoriasis

Intervention

Drug:
• Roflumilast foam 0.3%
experimental
• Vehicle foam
experimental

Locations

Country	Name	City	State
Australia	Arcutis Biotherapeutics Clinical Site 50	East Melbourne	Victoria
Australia	Arcutis Biotherapeutics Clinical Site 54	Hectorville	South Australia
Australia	Arcutis Biotherapeutics Clinical Site 51	Kogarah	New South Wales
Australia	Arcutis Biotherapeutics Clinical Site 52	Westmead	New South Wales
Bulgaria	Arcutis Biotherapeutics Clinical Site 11	Pleven
Bulgaria	Arcutis Biotherapeutics Clinical Site 13	Sevlievo
Bulgaria	Arcutis Biotherapeutics Clinical Site 10	Sofia
Bulgaria	Arcutis Biotherapeutics Clinical Site 14	Sofia
Bulgaria	Arcutis Biotherapeutics Clinical Site 12	Stara Zagora
Canada	Arcutis Biotherapeutics Clinical Site 61	Barrie	Ontario
Canada	Arcutis Biotherapeutics Clinical Site 64	Calgary	Alberta
Canada	Arcutis Biotherapeutics Clinical Site 60	London	Ontario
Canada	Arcutis Biotherapeutics Clinical Site 66	Montréal	Quebec
Canada	Arcutis Biotherapeutics Clinical Site 62	Peterborough	Ontario
Canada	Arcutis Biotherapeutics Clinical Site 63	Waterloo	Ontario
Canada	Arcutis Biotherapeutics Clinical Site 65	Westmount	Quebec
United States	Arcutis Biotherapeutics Site 70	Arlington	Texas
United States	Arcutis Biotherapeutics Clinical Site 76	Austin	Texas
United States	Arcutis Biotherapeutics Clinical Site 96	Bexley	Ohio
United States	Arcutis Biotherapeutics Clinical Site 91	Boynton Beach	Florida
United States	Arcutis Biotherapeutics Clinical Site 80	Broomall	Pennsylvania
United States	Arcutis Biotherapeutics Clinical Site 86	College Station	Texas
United States	Arcutis Biotherapeutics Clinical Site 20	Coral Gables	Florida
United States	Arcutis Biotherapeutics Clinical Site 79	Covington	Louisiana
United States	Arcutis Biotherapeutics Clinical Site 21	Cromwell	Connecticut
United States	Arcutis Biotherapeutics Clinical Site 72	Fremont	California
United States	Arcutis Biotherapeutics Clinical Site 73	Fridley	Minnesota
United States	Arcutis Biotherapeutics Clinical Site 87	High Point	North Carolina
United States	Arcutis Biotherapeutics Clinical Site 74	Houston	Texas
United States	Arcutis Biotherapeutics Clinical Site 78	Indianapolis	Indiana
United States	Arcutis Biotherapeutics Clinical Site 77	Louisville	Kentucky
United States	Arcutis Biotherapeutics Clinical Site 94	Metairie	Louisiana
United States	Arcutis Biotherapeutics Clinical Site 88	Miami	Florida
United States	Arcutis Biotherapeutics Clinical Site 90	Miami	Florida
United States	Arcutis Biotherapeutics Clinical Site 97	Murfreesboro	Tennessee
United States	Arcutis Biotherapeutics Clinical Site 81	Norfolk	Virginia
United States	Arcutis Biotherapeutics Clinical Site 89	Pflugerville	Texas
United States	Arcutis Biotherapeutics Clinical Site 95	Plainfield	Indiana
United States	Arcutis Biotherapeutics Clinical Site 82	Portland	Oregon
United States	Arcutis Biotherapeutics Clinical Site 98	Portsmouth	New Hampshire
United States	Arcutis Biotherapeutics Clinical Site 75	Richmond	Virginia
United States	Arcutis Biotherapeutics Clinical Site 71	Rogers	Arkansas
United States	Arcutis Biotherapeutics Clinical Site 99	Rolling Meadows	Illinois
United States	Arcutis Biotherapeutics Clinical Site 84	Saint Joseph	Missouri
United States	Arcutis Biotherapeutics Clinical Site 93	San Antonio	Texas
United States	Arcutis Biotherapeutics Clinical Site 85	San Diego	California
United States	Arcutis Biotherapeutics Clinical Site 83	Sweetwater	Florida

Sponsors (1)

Lead Sponsor	Collaborator
Arcutis Biotherapeutics, Inc.

Countries where clinical trial is conducted

United States,  Australia,  Bulgaria,  Canada, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of Participants Achieving Success in the Scalp Investigator Global Assessment (S-IGA) Scale	The number of participants achieving success in the S-IGA scale is presented for each arm. Success is defined as an S-IGA score of 0 ('clear') or 1 ('almost clear'), plus a 2-grade improvement from baseline.The S-IGA is 5-point scale assessing the severity of plaque psoriasis on the scalp, with scores ranging from 0 ('clear') to 4 ('severe'). Higher scores indicate greater symptom severity.	Week 8
Secondary	Number of Participants Achieving Body Investigator Global Assessment (B-IGA) Success at Week 8	The number of participants achieving success in the B-IGA scale is presented for each arm. Success is defined as a B-IGA score of 0 ('clear') or 1 ('almost clear'), plus a 2-grade improvement from baseline. The B-IGA is 5-point scale assessing the severity of plaque psoriasis on the body, with scores ranging from 0 ('clear') to 4 ('severe'). Higher scores indicate greater symptom severity.	Week 8
Secondary	Number of Participants Achieving Success in Scalp Itch Numerical Rating Scale (SI-NRS) Score	The number of participants with a baseline SI-NRS score =4 who achieve success (a =4-point improvement from Baseline) at Weeks 2, 4, and 8 is presented for each arm. The SI-NRS is a participant-reported rating of severity of itch at its highest intensity during the previous 24-hour period. The scale ranges from 0 ('no itch') to 10 ('worst imaginable itch'), with higher scores indicating greater symptom severity. Results are based on observed data only.	Baseline and Weeks 2, 4, 8
Secondary	Change From Baseline in Psoriasis Symptoms Diary (PSD) Score	The change from baseline in total PSD scores at Weeks 4 and 8 is presented for each arm. The PSD is a 16-item questionnaire asking subjects to rate the severity of psoriasis-related symptoms in the past 24 hours. Each question is scored from 0 ("no symptoms") to 10 ("worst imaginable symptoms"). Scores range from 0 to 160, with higher scores indicating greater symptom severity.	Baseline and Weeks 4 and 8
Secondary	Time to Achieve a 50% Reduction From Baseline in Psoriasis Scalp Severity Index (PSSI-50) Score	The time to achieve PSSI-50 (i.e., a 50% reduction from baseline in PSSI score) is presented for each arm. The PSSI measures the extent of psoriasis involvement and the severity of erythema, induration, and desquamation of the scalp. Involvement and severity of psoriasis for the PSSI is scored using a scale of 0 to 72, where 0 = no psoriasis and higher scores indicating greater symptom severity. Results are based on observed data only.	Up to 8 weeks
Secondary	Number of Participants Achieving Psoriasis Scalp Severity Index-75 (PSSI-75)	The number of participants achieving a 75% reduction in PSSI score (i.e., PSSI-75) from baseline. The PSSI measures the extent of psoriasis involvement and the severity of erythema, induration, and desquamation of the scalp. Involvement and severity of psoriasis for the PSSI is scored using a scale of 0 to 72, where 0 = no psoriasis and higher scores indicate greater symptom severity. Results are based on observed data only.	Week 8
Secondary	Number of Participants Achieving PSSI-90	The number of participants achieving a 90% reduction from baseline PSSI score (i.e., PSSI-90) is presented for each arm. The PSSI measures the extent of psoriasis involvement and the severity of erythema, induration, and desquamation of the scalp. Involvement and severity of psoriasis for the PSSI is scored using a scale of 0 to 72, where 0 = no psoriasis and higher scores indicate greater symptom severity. Results are based on observed data only.	Baseline and Week 8